Print

RV 135

Phase I/II trial intended to evaluate the tolerance and immune response to an ALVAC-HIV (vCP1521) and gp120 from a primary strain of subtype E. Dose-response trial of gp120 booster.

Trial Details:

I/II Completed
Walter Reed Army Institute of Research (WRAIR), April 01, 2000
ALVAC-HIV vCP1521,gp120 C4-V3
ALVAC-HIV vCP1521 Viral Vector - Pox
gp120 C4-V3 Protein
Thailand 120